Zhitong Finance App News, Yiming Angko-B (01541.HK) issued an announcement. According to the license and cooperation agreement, the company agreed to grant Axion an exclusive license to research, develop and commercialize a number of bispecific antibodies targeting programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) (including the candidate product IMM2510), as well as a number of monoclonal antibodies targeting cytotoxic T-lymphocyte-related protein 4 (CTLA-4), outside of Greater China.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Yiming Angko-B (01541.HK) issued an announcement. According to the license and cooperation agreement, the company agreed to grant Axion an exclusive license to research, develop and commercialize a number of bispecific antibodies targeting programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) (including the candidate product IMM2510), as well as a number of monoclonal antibodies targeting cytotoxic T-lymphocyte-related protein 4 (CTLA-4), outside of Greater China.